CD274 and non-small cell lung carcinoma: Currently, the launch of an antiprogrammed cell death ligand-1 (PD-L1) antibody represented a significant breakthrough for patients with advanced solid tumors.4 Strikingly, blockade of PD-L1 induced durable tumor regression and prolonged disease stabilization in patients with advanced NSCLC.